The BI-RADS-US reporting system assessment categories are as follows: 1. category 0: assessment is incomplete and requires further imaging evaluation. 2.Category 1: Negative: no abnormal findings on ultrasound. 3.Category 2: benign finding/findings: the report is fundamentally non-malignant. A unilateral cyst would fall into this category. Intramammary lymph nodes (which may still be included in category 1), breast implants, stable post-surgical changes and fibroadenomas with no changes found on serial ultrasound studies also fall into category 2. 4. category 3 (category 3): probable benign finding (probable benign finding), short-term follow-up is recommended. Based on clinical experience and the expansion of mammography, a substantial mass with well-defined margins, oval shape and horizontal orientation is most likely to be a fibroadenoma, with a risk of malignancy of less than 2%. Short-term follow-up is increasingly becoming the management strategy. Complex cysts and clusters of small cysts that cannot be palpated can also be included in this category for short-term follow-up. 5, Category 4: Suspicious abnormality, which should be considered for biopsy. The risk of malignancy of such lesions is moderate, with a probability of 3-94%. These lesions should be classified as low suspicion of malignancy, moderate suspicion, or high probability of malignancy. In general, tissue sampling is required for category 4 lesions. Substantial masses that do not have all the ultrasound features of fibroadenomas and other benign lesions are included in this category. 6, Category 5 (category 5): Highly suggestive of malignancy (almost certainly malignant) and appropriate measures should be taken. Ultrasound findings classified in this category have a 95% or higher risk of malignancy, and thus definitive treatment should be considered at the outset. With the increased use of anterior lymph node imaging techniques to evaluate lymph node metastases, with the increased use of neoadjuvant chemotherapy for massive malignancies, or for those masses that are difficult to identify, percutaneous sampling, most often with image-guided fine-needle biopsy, may provide a histopathologic diagnosis. 7, Category 6 (category 6): biopsy-proven malignancy (known biopsy-proven malignancy), appropriate measures should be taken. Patients who have biopsy-proven malignancy before seeking treatment fall into this category. Treatment includes neoadjuvant chemotherapy, surgical mass excision or mastectomy.